Compare LAES & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | FDMT |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 695.3M |
| IPO Year | 2022 | 2019 |
| Metric | LAES | FDMT |
|---|---|---|
| Price | $2.83 | $12.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 18.2M | 1.1M |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.99 | $4.11 |
| 52 Week High | $8.71 | $14.00 |
| Indicator | LAES | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 59.77 |
| Support Level | $2.59 | $8.52 |
| Resistance Level | $3.40 | $14.00 |
| Average True Range (ATR) | 0.23 | 1.04 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 11.81 | 60.47 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).